Lung protection of Chimonanthus nitens Oliv. essential oil driven by the control of intestinal disorders and dysbiosis through gut-lung crosstalk

Life Sci. 2023 Nov 15:333:122156. doi: 10.1016/j.lfs.2023.122156. Epub 2023 Oct 5.

Abstract

This work aimed to investigate whether Chimonanthus nitens Oliv. essential oil (CEO)-mediated lung protection was implicated in gut-lung crosstalk. Results showed that CEO attenuated lung and intestinal impairment by improving histopathological changes and inhibiting TLR4/NF-κB signaling pathway in LPS-stimulated rats, suggesting that there might be a mechanism for its lung protection involved in gut-lung interaction through manipulating the overlap in pathological changes via the similar inflammatory response. Furthermore, CEO-triggered intestinal protection was in parallel with the mitigation of ROS production, apoptosis, Ca2+ transport and mitochondrial membrane potential loss in vivo, and its intestinal protection was confirmed in vitro through IEC-6 cells. Importantly, a combination with CEO and LPS significantly remodeled gut microbiota composition compared with LPS alone in rats, while no significant impact on lung microbiota. Therefore, CEO-exerted lung protection was linked to gut and lung interactions involvement with the control of intestinal disorders and dysbiosis.

Keywords: Chimonanthus nitens Oliv. essential oil; Gut microbiota; Intestinal protection; LPS-stimulated rats; Lung protection; TLR4/NF-κB signaling pathway.

MeSH terms

  • Animals
  • Dysbiosis
  • Intestinal Diseases*
  • Lipopolysaccharides
  • Lung / metabolism
  • NF-kappa B / metabolism
  • Oils, Volatile* / pharmacology
  • Rats
  • Toll-Like Receptor 4 / metabolism

Substances

  • Lipopolysaccharides
  • Oils, Volatile
  • Toll-Like Receptor 4
  • NF-kappa B